Literature DB >> 16482539

Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections.

Sardar Sindhu1, Emil Toma, Paulo Cordeiro, Rasheed Ahmad, Richard Morisset, José Menezes.   

Abstract

TH1/TH2 cytokines' imbalance is critical to HIV-1 progression and pathogenesis. Opportunistic infections-related cytokine perturbations in the setting of highly active antiretroviral therapy (HAART) are unclear. The objective of this cross-sectional study was to identify the relationship between TH1/TH2 cytokines and viremia in HAART patients with/without opportunistic infections. Sera from 17 HAART patients with and 43 without opportunistic infections, and 20 HIV-seronegative controls were used to measure the levels of IL-2, IFN-gamma, IL-4, and IL-10 proteins and mRNAs by ELISA and RNase protection assays, respectively. Ex vivo cytokine production by the CD4+/CD8+ T cells from four low and four high viremia patients randomly selected from non-opportunistic infection group was also evaluated. Serum IL-2 and IFN-gamma levels were lower (P < 0.05) in patients than controls; this reduction was more pronounced for IFN-gamma in non-opportunistic infection patients. IL-4 and IL-10 were higher in patients than controls; this elevation was more remarkable in patients with opportunistic infections. Serum TH1/TH2 cytokine levels correlated with viremia. In vitro cytokine production assays showed that CD4+ T cells from low viremia patients mainly produced IL-2 and IFN-gamma, CD8+ T cells from high viremia patients produced IL-4, and both subsets comparably produced IL-10 in patients with similar viremia. Positive correlations between sera/supernatant proteins and cellular mRNAs were also found statistically significant (P < 0.05). It was therefore concluded that in vivo TH1/TH2 cytokine levels in HAART patients and their ex vivo production by the CD4+/CD8+ T cells correlated with viremia and were also modulated by the presence of opportunistic infections in these patients. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16482539     DOI: 10.1002/jmv.20558

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection.

Authors:  Rodolfo Silva; Susan Moir; Lela Kardava; Karen Debell; Venkateswara R Simhadri; Sara Ferrando-Martínez; Manuel Leal; José Peña; John E Coligan; Francisco Borrego
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

2.  Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation.

Authors:  Fabien Pitoiset; Thomas Vazquez; Beatrice Levacher; Djamel Nehar-Belaid; Nicolas Dérian; James Vigneron; David Klatzmann; Bertrand Bellier
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

3.  Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.

Authors:  Wendy K Nevala; Celine M Vachon; Alexey A Leontovich; Christopher G Scott; Michael A Thompson; Svetomir N Markovic
Journal:  Clin Cancer Res       Date:  2009-02-24       Impact factor: 12.531

Review 4.  Micronutrients, N-acetyl cysteine, probiotics and prebiotics, a review of effectiveness in reducing HIV progression.

Authors:  Ruben Hummelen; Jaimie Hemsworth; Gregor Reid
Journal:  Nutrients       Date:  2010-06-02       Impact factor: 5.717

5.  Altered T-Cell Subsets are Associated with Dysregulated Cytokine Secretion of CD4+ T Cells During HIV Infection.

Authors:  Di Wang; Yu Jiang; Yangzi Song; Yongqin Zeng; Cuilin Li; Xinyue Wang; Ying Liu; Jiang Xiao; Yaxian Kong; Hongxin Zhao
Journal:  J Inflamm Res       Date:  2021-10-07

6.  Is human immunodeficiency virus infection a risk factor for Strongyloides stercoralis hyperinfection and dissemination.

Authors:  Marc O Siegel; Gary L Simon
Journal:  PLoS Negl Trop Dis       Date:  2012-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.